Avadel Cns Drug Patent Portfolio
Avadel Cns owns 1 orange book drug protected by 30 US patents Given below is the list of Avadel Cns's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11779557 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 16 Mar, 2042 | Active |
| US11583510 | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal | 07 Feb, 2042 | Active |
| US10925844 | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state | 28 Feb, 2040 | Active |
| US10272062 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US10736866 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US10952986 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US10973795 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US11000498 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US11052061 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US11065224 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US11400065 | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state | 21 Jul, 2037 | Active |
| US11504347 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US11602512 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US11602513 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US11766418 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US11826335 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US11839597 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US11896572 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US11986451 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US12097175 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US12097176 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US12109186 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US12115142 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US12115143 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US12115144 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US12115145 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US12128021 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US12138239 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US12144793 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | 21 Jul, 2037 | Active |
| US12226377 | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state | 21 Jul, 2037 | Active |
Latest Legal Activities on Avadel Cns's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Avadel Cns.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 May, 2024 | US10973795 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Apr, 2024 | US10952986 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 18 Mar, 2024 | US10925844 |
| Patent eGrant Notification | 13 Feb, 2024 | US11896572 |
|
Recordation of Patent Grant Mailed
Critical
| 13 Feb, 2024 | US11896572 |
|
Email Notification
Critical
| 13 Feb, 2024 | US11896572 |
| Mail Patent eGrant Notification | 13 Feb, 2024 | US11896572 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 13 Feb, 2024 | US11896572 |
| Recordation of Patent eGrant | 13 Feb, 2024 | US11896572 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Feb, 2024 | US10736866 (Litigated) |
|
Email Notification
Critical
| 25 Jan, 2024 | US11896572 |
|
Issue Notification Mailed
Critical
| 24 Jan, 2024 | US11896572 |
|
Application Is Considered Ready for Issue
Critical
| 02 Jan, 2024 | US11896572 |
| Dispatch to FDC | 02 Jan, 2024 | US11896572 |
|
Email Notification
Critical
| 12 Dec, 2023 | US11839597 |
Avadel Cns's Family Patents
Avadel Cns Drug List
Given below is the complete list of Avadel Cns's drugs and the patents protecting them.
1. Lumryz
Lumryz is protected by 30 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11779557 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
16 Mar, 2042
(16 years from now)
| Active |
| US11583510 | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
07 Feb, 2042
(16 years from now)
| Active |
| US10925844 | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
28 Feb, 2040
(14 years from now)
| Active |
| US10272062 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US10736866 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US10952986 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US10973795 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US11000498 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US11052061 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US11065224 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US11400065 | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
21 Jul, 2037
(12 years from now)
| Active |
| US11504347 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US11602512 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US11602513 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US11766418 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US11826335 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US11839597 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US11896572 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US11986451 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US12097175 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US12097176 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US12109186 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US12115142 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US12115143 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US12115144 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US12115145 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US12128021 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US12138239 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US12144793 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
21 Jul, 2037
(12 years from now)
| Active |
| US12226377 | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
21 Jul, 2037
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lumryz's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List